Disease Overview
Acute lymphoblastic leukemia (ALL) is a hematological disease that is characterized by the proliferation of immature lymphoid cells in the bone marrow and peripheral blood. ALL is typically a disease of childhood, with over 70% of cases affecting children. Current treatment regimens have led to a cure rate of approximately 80% for children with ALL. However, the long-term prognosis for adult patients with ALL remains poor, with cure rates of only 30–40%.
Market Snapshot
Acute lymphoblastic leukemia (ALL) is a hematological disease that is characterized by the proliferation of immature lymphoid cells in the bone marrow and peripheral blood. ALL is typically a disease of childhood, with over 70% of cases affecting children. Current treatment regimens have led to a cure rate of approximately 80% for children with ALL. However, the long-term prognosis for adult patients with ALL remains poor, with cure rates of only 30–40%.
Market Snapshot
- The launches of generic tyrosine kinase inhibitors and emergence of CAR-T therapies will reshape the ALL market.
- TKIs are widely incorporated into treatment strategies for both adult and AYA patients with Ph+ ALL.
- Incident cases of ALL are expected to increase, and prognosis remains poor – especially among older adults.
- Generic erosion will signal an end to Gleevec’s Ph+ ALL dominance as targeted therapies build momentum.
Table of Contents
FORECAST: ACUTE LYMPHOBLASTIC LEUKEMIA (Published on 14 April 2016)
Overview
Executive Summary
Market Overview And Trends
Market Definition And Methodology
Blincyto (Blinatumomab)
Ctl019
Gleevec (Imatinib)
Iclusig (Ponatinib)
Inotuzumab Ozogamicin
Jcar015
Marqibo (Vincristine)
Sprycel (Dasatinib)
Primary Research Methodology
Executive Summary
Market Overview And Trends
Market Definition And Methodology
Blincyto (Blinatumomab)
Ctl019
Gleevec (Imatinib)
Iclusig (Ponatinib)
Inotuzumab Ozogamicin
Jcar015
Marqibo (Vincristine)
Sprycel (Dasatinib)
Primary Research Methodology
TREATMENT: ACUTE LYMPHOBLASTIC LEUKEMIA (Published on 02 March 2016)
Overview
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Country Treatment Trees
Current Treatment Options
Prescribing Trends
Future Treatment
Executive Summary
Primary Research Methodology
Disease Definition And Diagnosis
Patient Segmentation
Country Treatment Trees
Current Treatment Options
Prescribing Trends
Future Treatment
EPIDEMIOLOGY: ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) (Published on 05 July 2018)
Overview
Disease Background
Methodology
Forecast
Bibliography
Disease Background
Methodology
Forecast
Bibliography
MARKETED DRUGS: ACUTE LYMPHOBLASTIC LEUKEMIA (Published on 13 April 2016)
Overview
Executive Summary
Product Overview
Product Profile: Blincyto
Product Profile: Gleevec
Product Profile: Iclusig
Product Profile: Sprycel
Executive Summary
Product Overview
Product Profile: Blincyto
Product Profile: Gleevec
Product Profile: Iclusig
Product Profile: Sprycel
PIPELINE: ACUTE LYMPHOBLASTIC LEUKEMIA (Published on 31 August 2017)
Overview
Executive Summary
Clinical Pipeline Overview
Latest Analyst Opinion
Appendix
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Ctl019
Product Profile (Late Stage): Jcar015
Product Profile (Late Stage): Inotuzumab Ozogamicin
Executive Summary
Clinical Pipeline Overview
Latest Analyst Opinion
Appendix
Additional Pharma Intelligence Pipeline Resources
Product Profile (Late Stage): Ctl019
Product Profile (Late Stage): Jcar015
Product Profile (Late Stage): Inotuzumab Ozogamicin
LIST OF FIGURES
Figure 1: Total sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 2: Total branded tyrosine kinase inhibitor sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 3: Gleevec sales for acute lymphoblastic leukemia compared to imatinib generics sales across the US, Japan, and five major EU markets, 2015–24
Figure 4: Combined CAR-T therapy revenues for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 5: Sales of therapies approved for the treatment of Ph-negative acute lymphoblastic leukemia across the US, Japan, and five major EU markets, 2015–24
Figure 6: Patient-based forecast methodology for acute lymphoblastic leukemia
Figure 7: Price sources and calculations, by country
Figure 8: Blincyto sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 9: CTL019 sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 10: Gleevec sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 11: Iclusig sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 12: Inotuzumab ozogamicin sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 13: JCAR015 sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 14: Marqibo sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 15: Sprycel sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 16: Segmentation by age and Ph status of patients with acute lymphoblastic leukemia, by country
Figure 17: Proportion of Ph+ AYA (15–39 years) acute lymphoblastic leukemia patients at each stage of therapy, by country
Figure 18: Proportion of Ph+ adult (=40 years) acute lymphoblastic leukemia patients at each stage of therapy, by country
Figure 19: Percentage of Ph+ AYA acute lymphoblastic leukemia patients receiving each type of induction treatment regimen, by country
Figure 20: Percentage of Ph+ adult acute lymphoblastic leukemia patients receiving each type of induction treatment regimen, by country
Figure 21: Proportion of Ph+ acute lymphoblastic leukemia patients receiving stem cell transplant following complete response to induction therapy, by country
Figure 22: Percentage uptake of TKIs for post-stem cell transplant therapy in Ph+ AYA acute lymphoblastic leukemia patients, by country
Figure 23: Percentage uptake of TKIs for post-stem cell transplant therapy in Ph+ adult acute lymphoblastic leukemia patients, by country
Figure 24: Percentage of Ph+ AYA acute lymphoblastic leukemia patients receiving each type of consolidation treatment regimen, by country
Figure 25: Percentage of Ph+ adult acute lymphoblastic leukemia patients receiving each type of consolidation treatment regimen, by country
Figure 26: Percentage of Ph+ AYA acute lymphoblastic leukemia patients receiving each type of maintenance treatment regimen, by country
Figure 27: Percentage of Ph+ adult acute lymphoblastic leukemia patients receiving each type of maintenance treatment regimen, by country
Figure 28: Top three treatment regimens for relapse/refractory therapy in Ph+ AYA acute lymphoblastic leukemia patients, by country
Figure 29: Top three treatment regimens for relapse/refractory therapy in Ph+ adult acute lymphoblastic leukemia patients, by country
Figure 30: Trends in incident cases of ALL in the US, Japan, and five major EU markets, by country, 2017–37
Figure 31: The authors drug assessment summary for marketed and late-stage pipeline drugs in acute lymphoblastic leukemia
Figure 32: Blincyto – SWOT analysis in acute lymphoblastic leukemia
Figure 33: The authors drug assessment summary for Blincyto in acute lymphoblastic leukemia
Figure 34: The authors drug assessment summary for Blincyto in acute lymphoblastic leukemia
Figure 35: Gleevec – SWOT analysis in acute lymphoblastic leukemia
Figure 36: The authors drug assessment summary for Gleevec in acute lymphoblastic leukemia
Figure 37: The authors drug assessment summary for Gleevec in acute lymphoblastic leukemia
Figure 38: Iclusig – SWOT analysis in acute lymphoblastic leukemia
Figure 39: The authors drug assessment summary for Iclusig in acute lymphoblastic leukemia
Figure 40: The authors drug assessment summary for Iclusig in acute lymphoblastic leukemia
Figure 41: Sprycel – SWOT analysis in acute lymphoblastic leukemia
Figure 42: The authors drug assessment summary for Sprycel in acute lymphoblastic leukemia
Figure 43: The authors drug assessment summary for Sprycel in acute lymphoblastic leukemia
Figure 44: SWOT analysis – CTL019 for acute lymphoblastic leukemia
Figure 45: The authors drug assessment summary for CTL019 in acute lymphoblastic leukemia
Figure 46: The authors drug assessment summary for CTL019 in acute lymphoblastic leukemia
Figure 47: Overview of CTL019 technology
Figure 48: SWOT analysis – JCAR015 for acute lymphoblastic leukemia
Figure 49: The authors drug assessment summary for JCAR015 in acute lymphoblastic leukemia
Figure 50: The authors drug assessment summary for JCAR015 in acute lymphoblastic leukemia
Figure 51: SWOT analysis – inotuzumab ozogamicin for acute lymphoblastic leukemia
Figure 52: The authors drug assessment summary for inotuzumab ozogamicin in acute lymphoblastic leukemia
Figure 53: The authors drug assessment summary for inotuzumab ozogamicin in acute lymphoblastic leukemia
Figure 2: Total branded tyrosine kinase inhibitor sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 3: Gleevec sales for acute lymphoblastic leukemia compared to imatinib generics sales across the US, Japan, and five major EU markets, 2015–24
Figure 4: Combined CAR-T therapy revenues for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 5: Sales of therapies approved for the treatment of Ph-negative acute lymphoblastic leukemia across the US, Japan, and five major EU markets, 2015–24
Figure 6: Patient-based forecast methodology for acute lymphoblastic leukemia
Figure 7: Price sources and calculations, by country
Figure 8: Blincyto sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 9: CTL019 sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 10: Gleevec sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 11: Iclusig sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 12: Inotuzumab ozogamicin sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 13: JCAR015 sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 14: Marqibo sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 15: Sprycel sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country, 2015–24
Figure 16: Segmentation by age and Ph status of patients with acute lymphoblastic leukemia, by country
Figure 17: Proportion of Ph+ AYA (15–39 years) acute lymphoblastic leukemia patients at each stage of therapy, by country
Figure 18: Proportion of Ph+ adult (=40 years) acute lymphoblastic leukemia patients at each stage of therapy, by country
Figure 19: Percentage of Ph+ AYA acute lymphoblastic leukemia patients receiving each type of induction treatment regimen, by country
Figure 20: Percentage of Ph+ adult acute lymphoblastic leukemia patients receiving each type of induction treatment regimen, by country
Figure 21: Proportion of Ph+ acute lymphoblastic leukemia patients receiving stem cell transplant following complete response to induction therapy, by country
Figure 22: Percentage uptake of TKIs for post-stem cell transplant therapy in Ph+ AYA acute lymphoblastic leukemia patients, by country
Figure 23: Percentage uptake of TKIs for post-stem cell transplant therapy in Ph+ adult acute lymphoblastic leukemia patients, by country
Figure 24: Percentage of Ph+ AYA acute lymphoblastic leukemia patients receiving each type of consolidation treatment regimen, by country
Figure 25: Percentage of Ph+ adult acute lymphoblastic leukemia patients receiving each type of consolidation treatment regimen, by country
Figure 26: Percentage of Ph+ AYA acute lymphoblastic leukemia patients receiving each type of maintenance treatment regimen, by country
Figure 27: Percentage of Ph+ adult acute lymphoblastic leukemia patients receiving each type of maintenance treatment regimen, by country
Figure 28: Top three treatment regimens for relapse/refractory therapy in Ph+ AYA acute lymphoblastic leukemia patients, by country
Figure 29: Top three treatment regimens for relapse/refractory therapy in Ph+ adult acute lymphoblastic leukemia patients, by country
Figure 30: Trends in incident cases of ALL in the US, Japan, and five major EU markets, by country, 2017–37
Figure 31: The authors drug assessment summary for marketed and late-stage pipeline drugs in acute lymphoblastic leukemia
Figure 32: Blincyto – SWOT analysis in acute lymphoblastic leukemia
Figure 33: The authors drug assessment summary for Blincyto in acute lymphoblastic leukemia
Figure 34: The authors drug assessment summary for Blincyto in acute lymphoblastic leukemia
Figure 35: Gleevec – SWOT analysis in acute lymphoblastic leukemia
Figure 36: The authors drug assessment summary for Gleevec in acute lymphoblastic leukemia
Figure 37: The authors drug assessment summary for Gleevec in acute lymphoblastic leukemia
Figure 38: Iclusig – SWOT analysis in acute lymphoblastic leukemia
Figure 39: The authors drug assessment summary for Iclusig in acute lymphoblastic leukemia
Figure 40: The authors drug assessment summary for Iclusig in acute lymphoblastic leukemia
Figure 41: Sprycel – SWOT analysis in acute lymphoblastic leukemia
Figure 42: The authors drug assessment summary for Sprycel in acute lymphoblastic leukemia
Figure 43: The authors drug assessment summary for Sprycel in acute lymphoblastic leukemia
Figure 44: SWOT analysis – CTL019 for acute lymphoblastic leukemia
Figure 45: The authors drug assessment summary for CTL019 in acute lymphoblastic leukemia
Figure 46: The authors drug assessment summary for CTL019 in acute lymphoblastic leukemia
Figure 47: Overview of CTL019 technology
Figure 48: SWOT analysis – JCAR015 for acute lymphoblastic leukemia
Figure 49: The authors drug assessment summary for JCAR015 in acute lymphoblastic leukemia
Figure 50: The authors drug assessment summary for JCAR015 in acute lymphoblastic leukemia
Figure 51: SWOT analysis – inotuzumab ozogamicin for acute lymphoblastic leukemia
Figure 52: The authors drug assessment summary for inotuzumab ozogamicin in acute lymphoblastic leukemia
Figure 53: The authors drug assessment summary for inotuzumab ozogamicin in acute lymphoblastic leukemia
LIST OF TABLES
Table 1: Summary of drug classes and molecules in The authors acute lymphoblastic leukemia patient-based forecast
Table 2: Exchange rates used for calculating prices
Table 3: Patent expiry dates for key marketed brands in acute lymphoblastic leukemia in the US, Japan, and five major EU markets, 2015–24
Table 4: Estimated approval dates of key late-stage pipeline products in acute lymphoblastic leukemia in the US, Japan, and five major EU markets, 2015–24
Table 5: Blincyto sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 6: CTL019 sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 7: Gleevec sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 8: Iclusig sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 9: Inotuzumab ozogamicin sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 10: JCAR015 sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 11: Marqibo sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 12: Sprycel sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 13: Hematologists surveyed for the acute lymphoblastic leukemia primary research study, 2015
Table 14: Hematologists surveyed for the acute lymphoblastic leukemia primary research study, 2015
Table 15: Approved TKIs indicated for the treatment of adults with acute lymphoblastic leukemia
Table 16: WHO classification of ALL
Table 17: Cancer registry databases used as a source of ALL incidence data, by country
Table 18: Forecasting methodology for ALL incidence, by country and age group
Table 19: Proportions and sources used to segment incident ALL cases by immunophenotype
Table 20: Proportions used to segment incident ALL cases by chromosomal and molecular abnormality
Table 21: Sources of survival data used to estimate B-cell ALL prevalence, by country
Table 22: Incident cases of ALL in the US, Japan, and five major EU markets, by country, 2017–37
Table 23: Key marketed drugs for acute lymphoblastic leukemia
Table 24: Key marketed drugs for acute lymphoblastic leukemia, by approval date
Table 25: Blincyto drug profile
Table 26: Pivotal clinical trial data for Blincyto in acute lymphoblastic leukemia
Table 27: Blincyto ongoing late-phase clinical trials in acute lymphoblastic leukemia
Table 28: Gleevec drug profile
Table 29: Pivotal clinical trial data for Gleevec in acute lymphoblastic leukemia
Table 30: Iclusig drug profile
Table 31: Pivotal clinical trial data for Iclusig in acute lymphoblastic leukemia
Table 32: Sprycel drug profile
Table 33: Overview of pivotal trial data for Sprycel in acute lymphoblastic leukemia
Table 34: Phase III pipeline candidates under development for acute lymphoblastic leukemia
Table 35: CTL019 drug profile
Table 36: Overview of ongoing trials for CTL019 in acute lymphoblastic leukemia
Table 37: Overview of early-phase data for CTL019 in acute lymphoblastic leukemia
Table 38: JCAR015 drug profile
Table 39: Overview of ongoing trials for JCAR015 in acute lymphoblastic leukemia
Table 40: Overview of early-phase data for JCAR015 in acute lymphoblastic leukemia
Table 41: Inotuzumab ozogamicin drug profile for acute lymphoblastic leukemia
Table 42: Ongoing clinical trial development of inotuzumab ozogamicin in acute lymphoblastic leukemia
Table 2: Exchange rates used for calculating prices
Table 3: Patent expiry dates for key marketed brands in acute lymphoblastic leukemia in the US, Japan, and five major EU markets, 2015–24
Table 4: Estimated approval dates of key late-stage pipeline products in acute lymphoblastic leukemia in the US, Japan, and five major EU markets, 2015–24
Table 5: Blincyto sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 6: CTL019 sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 7: Gleevec sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 8: Iclusig sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 9: Inotuzumab ozogamicin sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 10: JCAR015 sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 11: Marqibo sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 12: Sprycel sales for acute lymphoblastic leukemia across the US, Japan, and five major EU markets, by country ($m), 2015–24
Table 13: Hematologists surveyed for the acute lymphoblastic leukemia primary research study, 2015
Table 14: Hematologists surveyed for the acute lymphoblastic leukemia primary research study, 2015
Table 15: Approved TKIs indicated for the treatment of adults with acute lymphoblastic leukemia
Table 16: WHO classification of ALL
Table 17: Cancer registry databases used as a source of ALL incidence data, by country
Table 18: Forecasting methodology for ALL incidence, by country and age group
Table 19: Proportions and sources used to segment incident ALL cases by immunophenotype
Table 20: Proportions used to segment incident ALL cases by chromosomal and molecular abnormality
Table 21: Sources of survival data used to estimate B-cell ALL prevalence, by country
Table 22: Incident cases of ALL in the US, Japan, and five major EU markets, by country, 2017–37
Table 23: Key marketed drugs for acute lymphoblastic leukemia
Table 24: Key marketed drugs for acute lymphoblastic leukemia, by approval date
Table 25: Blincyto drug profile
Table 26: Pivotal clinical trial data for Blincyto in acute lymphoblastic leukemia
Table 27: Blincyto ongoing late-phase clinical trials in acute lymphoblastic leukemia
Table 28: Gleevec drug profile
Table 29: Pivotal clinical trial data for Gleevec in acute lymphoblastic leukemia
Table 30: Iclusig drug profile
Table 31: Pivotal clinical trial data for Iclusig in acute lymphoblastic leukemia
Table 32: Sprycel drug profile
Table 33: Overview of pivotal trial data for Sprycel in acute lymphoblastic leukemia
Table 34: Phase III pipeline candidates under development for acute lymphoblastic leukemia
Table 35: CTL019 drug profile
Table 36: Overview of ongoing trials for CTL019 in acute lymphoblastic leukemia
Table 37: Overview of early-phase data for CTL019 in acute lymphoblastic leukemia
Table 38: JCAR015 drug profile
Table 39: Overview of ongoing trials for JCAR015 in acute lymphoblastic leukemia
Table 40: Overview of early-phase data for JCAR015 in acute lymphoblastic leukemia
Table 41: Inotuzumab ozogamicin drug profile for acute lymphoblastic leukemia
Table 42: Ongoing clinical trial development of inotuzumab ozogamicin in acute lymphoblastic leukemia
